Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations

Casey, Murray Joseph; Synder, C.; Bewtra, Chhanda; Narod, Steven A.; Watson, Patrice; Lynch, Henry T.

doi:10.1016/j.ygyno.2005.01.039

Cited by 90 publications

(64 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is not unexpected in the light of previous studies reporting a low risk of PPC. 27,31,32 In the recent study by Finch et al 33 in women who had undergone SO, the annual risk of PPC was estimated to be 0.217% in BRCA1 carriers and 0.167% in BRCA2 carriers. On the basis of these estimates, less than 1 case would have been expected in our series.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Prophylactic salpingo‐oophorectomy (SO), which is recommended in BRCA1/2 mutation carriers, still needs to be reappraised.METHODS.In all, 89 BRCA1/BRCA2 mutation carriers underwent SO between 1994–2004. Past medical and familial history, SO, results and survival after SO were analyzed.RESULTS.The series consisted of 56 BRCA1 and 33 BRCA2 mutation carriers. All but 1 had a family history of breast (BC) and/or ovarian cancer; 42 BRCA1 and 31 BRCA2 had a personal history of BC. The median age at SO was 44 (BRCA1) and 49.5 (BRCA2) years for women without previous BC (not significant) and 48 (BRCA1) and 53 BRCA2) years (P = .03) for women with previous BC. Occult ovarian (n = 2) and/or fallopian (n = 3) carcinomas were found in 4 patients (4.5%): 1 experienced recurrence (4 years), 2 are disease‐free (26 and 38 months of follow‐up), and 1 died from BC (12 months). Among the other 69 patients with previous BC (median follow‐up, 42 months), 14 developed ipsilateral or contralateral BC and 8 developed metastatic disease. Among the 16 patients without previous BC (median follow‐up, 27 months), 3 developed BC. Of the 89 patients, 85 are still alive: 3 died from BC and 1 died from pancreatic cancer. No peritoneal malignancy was observed.CONCLUSIONS.This study shows that prophylactic SO remains an important option for BRCA1/2 mutation carriers as asymptomatic ovarian/fallopian cancers were found in 4.5% of patients. However, a longer follow‐up and larger series are required to more precisely evaluate the benefits of this procedure in terms of BC incidence, peritoneal malignancy, or recurrence. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Laki

Kirova

This

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…134 -136 However, after risk-reducing oophorectomy, the peritoneum remains at risk for primary peritoneal cancer, with rates of ϳ2% after surgery. 55,137 Rebbeck et al 130 also found a 53% risk reduction for breast cancer in women undergoing bilateral prophylactic oophorectomy. These observations were consistent with the findings of Olopade and Artioli.…”

Section: Primary Preventionmentioning

confidence: 98%

“…54 BRCA1 mutation carriers are also at risk of primary papillary serous carcinoma of the peritoneum, a malignancy that is indistinguishable from serous epithelial ovarian carcinoma, with cumulative risks of 3.9% to 4.3% 20 years after oophorectomy. 55,56 The risk of prostate cancer in male BRCA1 carriers is increased with a relative risk of ϳ1.8 57 although this risk may vary significantly depending on the location of the BRCA1 mutation. 58 Furthermore, such cancers do not typically demonstrate a younger than usual age at diagnosis.…”

Section: Brca1-other Related Cancer Risksmentioning

confidence: 99%

See 1 more Smart Citation

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

Petrucelli

Daly

Feldman

2010

Genetics in Medicine

361

255

View full text Add to dashboard Cite

“…Primary peritoneal cancers have been reported in women with BRCA1/2 mutations following PO with an estimated frequency of 2-4%, and occur more frequently in BRCA1 compared to BRCA2 carriers (Piver et al, 1993;Kauff et al, 2002;Rebbeck et al, 2002;Casey et al, 2005). Primary peritoneal cancer may occur either owing to an occult ovarian cancer focus or from carcinoma arising de novo in peritoneal mesothelium.…”

Section: Primary Peritoneal Cancer and Fallopian Tube Carcinomamentioning

confidence: 99%

Clinical management of BRCA1 and BRCA2 mutation carriers

Domchek

Weber

2006

Oncogene

View full text Add to dashboard Cite

The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary sitespecific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions. Oncogene (2006) 25, 5825-5831. doi:10.1038/sj.onc.1209881Keywords: BRCA1; BRCA2; oophorectomy; breast cancer; ovarian cancer; management Management of ovarian cancer risk Prophylactic oophorectomyThe lifetime risk of ovarian cancer for women with BRCA1 mutations is estimated at 40-50% (Ford et al., 1994;Antoniou et al., 2003;King et al., 2003) and in those with BRCA2 mutations, at 10-20% (1999;Antoniou et al., 2003;King et al., 2003). We and others have shown conclusively that prophylactic oophorectomy (PO) in women with BRCA1/2 mutations reduces the risk of ovarian cancer by approximately 90% (Kauff et al., 2002;Rebbeck et al., 2002;Rutter et al., 2003;Domchek et al., 2006). Data with short-term follow-up also suggests that oophorectomy is associated with an improvement in breast cancer-specific survival, ovarian cancer-specific survival and overall survival (Domchek et al., 2006) (Figure 1). Table 1 reports the details of studies examining PO in BRCA1/2 mutation carriers. Rebbeck et al. (2002) examined 551 women from 11 centers in North America and Europe who either did (n ¼ 259) or did not (n ¼ 292) undergo PO, with a mean follow-up of over 8 years in each group. Eight PO subjects (3.1%) were diagnosed with ovarian cancer or primary peritoneal cancer at or following PO compared with 58 controls (19.9%). Six of the eight PO subjects diagnosed with ovarian cancer were diagnosed at the time of PO, all of which were stage I. After excluding these six cases, only two women (both with BRCA1 mutations) who underwent PO subsequently developed primary peritoneal cancer. Compared with women who did not undergo PO, the occurrence of post-PO ovarian cancer corresponded to a hazard ratio (HR) of 0.04 (95% confidence interval (CI): 0.01-0.16). In addition to this striking reduction in the risk of ovarian cancer, an approximately 50% breast cancer risk reduction after PO was also observed (HR ¼ 0.47; 95% CI: 0.29-0.77). In an another study with similar results, Kauff et al. (2002) identified 170 women with BRCA1/2 mutations who had not previously undergone PO, who then chose to either undergo ovarian cancer surveillance or undergo PO. During a mean follow-up of 24.2 months, ovarian cancer or primary peritoneal carcinoma was diagnosed in one of 98 women who chose to undergo PO compared to five ovarian or peritoneal cancers in the 72 women who chose surveillance. This risk reduction corresponded to a HR of 0.15 (95% CI: 0.02-1.31).Finally, ...

show abstract

Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations

Cited by 90 publications

References 77 publications

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Prophylactic salpingo‐oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2

Clinical management of BRCA1 and BRCA2 mutation carriers

Contact Info

Product

Resources

About